CHICAGO, United States — Moderna’s personalized mRNA cancer therapy Intismeran has delivered positive results in a late-stage melanoma trial conducted with Merck, sending Moderna shares sharply higher on Wednesday. The treatment, when combined with Merck’s Keytruda, met its main goal of reducing cancer recurrence and also achieved a key secondary goal involving the prevention of cancer spread.
Tag: Intismeran
Moderna Shares Surge After Cancer Vaccine Trial
NEW YORK, United States — Moderna shares surged in U.S. trading on Wednesday after the company and Merck reported positive Phase 3 results for their personalised mRNA cancer vaccine, Intismeran, in combination with Keytruda for melanoma patients. The breakthrough trial result also lifted Merck shares and became the standout development among several major premarket stock movers.